Seborrhea Overview:
Seborrhea is a chronic inflammatory skin disease characterized by the accumulation of greasy scales. It often appears as yellow, crusted, itchy patches and commonly affects the scalp (called dandruff). Other common areas affected by seborrhea include the face, ears, eyebrows, eyelids, navel, and genital area. The condition can be either primary (hereditary) or secondary (more common, with unclear cause). Factors such as hormones, stress, and yeast-like microorganisms contribute significantly to the development of this condition. Seborrhea can affect people of all ages, including infants, adults, and the elderly, and is more common in men and those with oily skin.
Request a detailed insight report on Seborrhea Pipeline Insights @ https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
of "Seborrhea Pipeline Insights 2024, "DelveInsight's report provides a detailed analysis of the ongoing clinical development activities and future growth prospects in the seborrhea therapeutics market.
Key Takeaways from the Sebum Pipeline Report:
- DelveInsight's Seborrhea Pipeline report presents a dynamic field with 3+ active companies working on 3+ pipeline therapies for the treatment of seborrhea.
- Leading companies such as Arcutis Biotherapeutics, Cutanea Life Sciences Inc., and Vyome Therapeutics are researching and evaluating new drugs to improve seborrhea treatment outcomes.
- Among the promising treatments in the seborrhea pipeline are ARQ154 (topical roflumilast foam) and other treatments in various stages of development.
Recent Developments in Seborrhea Pipeline Segment:
As of December 2023, the U.S. Food and Drug Administration (FDA) approved Zolibu (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in people 9 years of age and older. This approval introduces the first new mechanism of action for the treatment of seborrheic dermatitis in over 20 years.
Sebum Pipeline Analysis:
The report provides detailed insights into:
- Key companies involved in developing treatments for the seborrhea market.
- Evaluation of various therapeutic candidates categorized by development stage (early, mid, late stage).
- Analysis of companies involved in the development of targeted therapeutics, including companies with active and inactive (dormant or discontinued) projects.
- Explore new drugs in development, classified by stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and type of molecule.
- It provides an in-depth analysis of collaborations (including business-to-business and business-to-academic), licensing agreements, and funding details to advance the Seborrhea market.
Download Free Sample Page Report on Seborrhea Pipeline Insights @ https://www.delveinsight.com/sample-request/sebohrrea-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
New drugs for seborrhea:
ARQ154 (topical roflumilast foam): Arctis Biotherapeutics, Inc.
Since 2011, the US FDA has approved the systemic use of roflumilast to reduce exacerbations of chronic obstructive pulmonary disease (COPD). Arcutis Biotherapeutics Inc. recently announced positive topline results from a Phase 2 clinical trial evaluating ARQ-154, a topical foam formulation of roflumilast, as a potential treatment for seborrheic dermatitis. ARQ-154 is a foam-based version of a highly potent and selective PDE4 inhibitor.
Seborrhea Companies:
Several major companies are focusing on developing treatments for seborrhea, with Arcutis Biotherapeutics Inc. having the furthest-stage drug candidate currently in Phase II clinical trials.
DelveInsight's reports cover three or more products at various stages of clinical development.
- Post-production(Phase III)
- Mid-term products(Phase II)
- Early Stage Products(Phase I), in combination with preclinical and discovery stage candidates
- Discontinued and inactive candidates
The Seborrhea Pipeline report evaluates these drugs according to their effectiveness. Route of administration, which includes categories such as:
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Further, the products are classified as follows: Molecular Type, like:
- Monoclonal antibodies
- Low molecular weight
- peptide
For a comprehensive assessment of new Seborrhea Therapies and key players, download the sample report: Seborrhea Clinical Trials and Advancements @ https://www.delveinsight.com/sample-request/sebohrrea-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Therapeutic evaluations in the seborrhea pipeline include:
- Seborrheic rating by product type
- Stage evaluation of seborrhea
- Assessment of seborrhea by route of administration
- Assessment of seborrhea by molecular type
Download Seborrhea Sample ReportGet detailed insights into the Seborrhea Treatment Market @ https://www.delveinsight.com/report-store/sebohrrea-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr
Table of contents
- Introduction to the report
- Executive Summary
- Current Treatment Patterns for Seborrhea
- Seborrhea – A DelveInsight Analysis Perspective
- Treatment evaluation
- Seborrhea Late Stage Products (Phase III)
- Seborrhea Mid-stage Products (Phase II)
- Early Stage Products (Phase I)
- Preclinical and discovery stage products
- Inactive Products
- Dormant products
- Seborrhea Discontinued Products
- Seborrhea Product Profile
- Major Seborrhea Companies
- Seborrhea Major Products
- Inactive and Discontinued Products
- Unmet Needs in Seborrhea
- Future Outlook for Seborrhea
- Seborrhea Analyst Review
- Appendix
- Reporting Methods
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
